Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Allogeneic HSC and regulatory T cell  (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

View Full Paper
Ask AI
Bookmark
Share

Authors

LJLaura JohnstonARAndrew R. RezvaniEMEverett Meyer

Discussion

Loading...

Member takes

Overview

Phase 1 study shows Orca-T improves safety and reduces graft versus host disease in hematological malignancies.

Key Points

  • To evaluate the safety and feasibility of Orca-T in combination with reduced intensity conditioning for hematological malignancies.
  • Single-center, open-label, phase 1 feasibility study
  • Evaluated incidence of graft versus host disease and graft failure
  • Included patients with varying HLA matching
  • Utilized conditioning regimens with fludarabine, melphalan, and thiotepa
  • 49 patients treated with successful neutrophil engraftment in median of 15 days
  • 1-year cumulative incidence of acute graft versus host disease is 14%
  • 85% overall survival at 1 year with low non-relapse mortality

Cite This Study

Johnston et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfechttps://doi.org/10.1182/blood-2025-111
View Full Paper
Ask AI
Bookmark
Share